Commentary

Video

Translating BTK Inhibitor Data into Clinical Decision-Making

Author(s):

Mazyar Shadman, MD, MPH,Marc S. Hoffmann, MD

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Related Videos
Neil Iyengar, MD, and Chandler Park, MD, FACP
John M. Burke, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Related Content
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Chronic Lymphocytic Leukemia | stock.adobe.com
December 10th 2024

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

B-Cell Malignancies
December 9th 2024

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies